FDA Drug Approval: Type I vs. Type II Error Trade-Offs
This paper analyzes the tension between speed and thoroughness in the FDA drug approval process through the lens of Type I and Type II decision errors. Drawing on Miller, Benjamin, and North's discussion of benefit-cost trade-offs and Carpenter et al.'s research on review timelines, the paper traces how the FDA shifted from faster, riskier approvals toward longer, more cautious reviews following the 1962 amendment to the Food, Drug, and Cosmetic Act. It then examines evidence that review times have since shortened, evaluating whether this represents a return to Type I error orientation or simply greater efficiency through increased scientific staffing.
- Introduction: The Cost of Every Decision: Decision-making involves trade-offs and consequences
- Type I and Type II Errors in Drug Approval: Defining speed versus caution error types
- The Thalidomide Scandal and the FDA's Shift: 1962 amendment shifted FDA toward Type II errors
- Review Times and the Role of Staffing: Staffing levels, not user fees, drove faster reviews
- Interpreting the Data: Error Orientation or Efficiency?: Faster reviews may not mean less thorough analysis
- Conclusion: Workload Distribution and Consumer Perspective: Workload distribution determines true error orientation
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- It applies a clear economic framework — Type I and Type II errors — to a real-world regulatory debate, giving the analysis conceptual precision.
- It juxtaposes two empirical sources that appear to conflict, then resolves the tension analytically rather than dismissing either finding.
- The memo format is concise and purposeful; each paragraph advances the argument without digression.
Key academic technique demonstrated
The paper demonstrates source synthesis under tension: rather than treating Miller et al. and Carpenter et al. as contradictory, the author identifies a third variable — how staff resources are deployed — that reconciles both findings. This move from apparent contradiction to nuanced resolution is a hallmark of strong analytical writing at the undergraduate level.
Structure breakdown
The paper opens with a broad principle (every decision has costs and trade-offs), narrows to the FDA context, introduces the historical shift triggered by Thalidomide, then presents newer data on faster review times. The final two paragraphs form a conditional analysis — "if X, then Type I; if Y, then Type II" — ending with a consumer-centered value judgment. The reference list follows APA format throughout.
Introduction: The Cost of Every Decision
People in every walk of life must make decisions that affect, to some degree, the well-being of others. Everything comes with a cost — not simply in financial terms, but also in terms of opportunities no longer available once a particular decision is made. One chooses a course of action and thereby foregoes the other choices that were available. Each choice carries consequences, both anticipated and unforeseen. This benefit-cost dynamic and the web of consequences that result from the choices we make are an inescapable aspect of life (Miller, Benjamin, and North, 2005).
Type I and Type II Errors in Drug Approval
A hasty decision may have harmful, unintended consequences that might have been identified with more thorough pre-decision analysis. On the other hand, some people may be condemned to extended deprivation while lengthy analysis and deliberations continue. One can err on the side of immediacy — a Type I error — or on the side of caution — a Type II error. There are consequences, known and unknown, for both (Miller et al., 2005).
Create your account
Always verify citation format against your institution’s current style guide requirements.